Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time - PACE-CME

Humanised PCSK antibody lowers CV events in highrisk patients but LDLc lowering effects decline over time

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

LDL lowering for CVD prevention: From hypothesis to axiom
LDL lowering for CVD prevention: From hypothesis to axiom
ACC.17
LDL lowering for CVD prevention: From hypothesis to axiom
- Prof. John JP Kastelein
The implications of PCSK9 outcome trials for GPs
The implications of PCSK9 outcome trials for GPs
ACC.17
The implications of PCSK9 outcome trials for GPs
- Prof. Richard Hobbs, MD
PCSK9 outcome trials: The results put into perspective of other clinical developments
PCSK9 outcome trials: The results put into perspective of other clinical developments
ACC.17
PCSK9 outcome trials: The results put into perspective of other clinical developments
- Prof. Peter Sever
Initiating digoxin in AF patients associated with early hazard of sudden death
Initiating digoxin in AF patients associated with early hazard of sudden death
ACC.17
Initiating digoxin in AF patients associated with early hazard of sudden death
- Dr. Renato Lopes